These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34376803)

  • 1. Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia.
    Tadmor T; Benjamini O; Braester A; Rahav G; Rokach L
    Leukemia; 2021 Sep; 35(9):2727-2730. PubMed ID: 34376803
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.
    Roeker LE; Knorr DA; Thompson MC; Nivar M; Lebowitz S; Peters N; Deonarine I; Momotaj S; Sharan S; Chanlatte V; Hampton B; Butala L; Amato L; Richford A; Lunkenheimer J; Battiato K; Laudati C; Mato AR
    Leukemia; 2021 Sep; 35(9):2703-2705. PubMed ID: 33986431
    [No Abstract]   [Full Text] [Related]  

  • 3. COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.
    Del Poeta G; Bomben R; Polesel J; Rossi FM; Pozzo F; Zaina E; Cattarossi I; Varaschin P; Nanni P; Boschian Boschin R; Postorino M; Laureana R; Pasqualone G; Steffan A; Gentile M; Zucchetto A; Gattei V
    Hematol Oncol; 2021 Dec; 39(5):712-714. PubMed ID: 34462939
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.
    Parry H; McIlroy G; Bruton R; Ali M; Stephens C; Damery S; Otter A; McSkeane T; Rolfe H; Faustini S; Wall N; Hillmen P; Pratt G; Paneesha S; Zuo J; Richter A; Moss P
    Blood Cancer J; 2021 Jul; 11(7):136. PubMed ID: 34330895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.
    Molica S; Giannarelli D; Montserrat E
    Eur J Haematol; 2022 Mar; 108(3):264-267. PubMed ID: 34856031
    [No Abstract]   [Full Text] [Related]  

  • 6. Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.
    Blixt L; Bogdanovic G; Buggert M; Gao Y; Hober S; Healy K; Johansson H; Kjellander C; Mravinacova S; Muschiol S; Nilsson P; Palma M; Pin E; Smith CIE; Stromberg O; Sällberg Chen M; Zain R; Hansson L; Österborg A
    Leukemia; 2022 Feb; 36(2):476-481. PubMed ID: 34564699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
    Herishanu Y; Rahav G; Levi S; Braester A; Itchaki G; Bairey O; Dally N; Shvidel L; Ziv-Baran T; Polliack A; Tadmor T; Benjamini O;
    Blood; 2022 Feb; 139(5):678-685. PubMed ID: 34861036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.
    Monin L; Laing AG; Muñoz-Ruiz M; McKenzie DR; Del Molino Del Barrio I; Alaguthurai T; Domingo-Vila C; Hayday TS; Graham C; Seow J; Abdul-Jawad S; Kamdar S; Harvey-Jones E; Graham R; Cooper J; Khan M; Vidler J; Kakkassery H; Sinha S; Davis R; Dupont L; Francos Quijorna I; O'Brien-Gore C; Lee PL; Eum J; Conde Poole M; Joseph M; Davies D; Wu Y; Swampillai A; North BV; Montes A; Harries M; Rigg A; Spicer J; Malim MH; Fields P; Patten P; Di Rosa F; Papa S; Tree T; Doores KJ; Hayday AC; Irshad S
    Lancet Oncol; 2021 Jun; 22(6):765-778. PubMed ID: 33930323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T
    Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia.
    Parry H; McIlroy G; Bruton R; Damery S; Tyson G; Logan N; Davis C; Willett B; Zuo J; Ali M; Kaur M; Stephens C; Brant D; Otter A; McSkeane T; Rolfe H; Faustini S; Richter A; Lee S; Wandroo F; Shafeek S; Pratt G; Paneesha S; Moss P
    J Hematol Oncol; 2022 Jan; 15(1):3. PubMed ID: 35000597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
    Herzog Tzarfati K; Gutwein O; Apel A; Rahimi-Levene N; Sadovnik M; Harel L; Benveniste-Levkovitz P; Bar Chaim A; Koren-Michowitz M
    Am J Hematol; 2021 Oct; 96(10):1195-1203. PubMed ID: 34185336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer.
    Avanzato VA; Matson MJ; Seifert SN; Pryce R; Williamson BN; Anzick SL; Barbian K; Judson SD; Fischer ER; Martens C; Bowden TA; de Wit E; Riedo FX; Munster VJ
    Cell; 2020 Dec; 183(7):1901-1912.e9. PubMed ID: 33248470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.
    Herishanu Y; Avivi I; Levi S; Shefer G; Bronstein Y; Moshiashvili MM; Ziv T; Scarfò L; Perry C; Ghia P
    Blood Adv; 2022 Jan; 6(1):148-151. PubMed ID: 34614513
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
    Benjamini O; Rokach L; Itchaki G; Braester A; Shvidel L; Goldschmidt N; Shapira S; Dally N; Avigdor A; Rahav G; Lustig Y; Ben David SS; Fineman R; Paz A; Bairey O; Polliack A; Levy I; Tadmor T
    Haematologica; 2022 Mar; 107(3):625-634. PubMed ID: 34320789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
    Fox TA; Kirkwood AA; Enfield L; O'Reilly M; Arulogun S; D'Sa S; O'Nions J; Kavi J; Vitsaras E; Townsend W; Burns SO; Gohil SH; Cwynarski K; Thomson KJ; Noursadeghi M; Heyderman RS; Rampling T; Ardeshna KM; McCoy LE; Morris EC
    Br J Haematol; 2021 Dec; 195(5):706-709. PubMed ID: 34545952
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia.
    Roeker LE; Knorr DA; Pessin MS; Ramanathan LV; Thompson MC; Leslie LA; Zelenetz AD; Mato AR
    Leukemia; 2020 Nov; 34(11):3047-3049. PubMed ID: 32855439
    [No Abstract]   [Full Text] [Related]  

  • 17. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia.
    Pimpinelli F; Marchesi F; Piaggio G; Giannarelli D; Papa E; Falcucci P; Spadea A; Pontone M; Di Martino S; Laquintana V; La Malfa A; Di Domenico EG; Di Bella O; Falzone G; Ensoli F; Vujovic B; Morrone A; Ciliberto G; Mengarelli A
    J Hematol Oncol; 2021 Jul; 14(1):119. PubMed ID: 34325728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.
    Gobbi F; Buonfrate D; Moro L; Rodari P; Piubelli C; Caldrer S; Riccetti S; Sinigaglia A; Barzon L
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33807957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.